Compare Citius Pharmaceuticals Inc (CTXR) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Under Armour Inc Class A trades at $4.74 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 152× Citius Pharmaceuticals Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Under Armour Inc Class A for 18 Days on average.
| CTXR | UA | |
|---|---|---|
Market Cap | $13.62M | $2.07B |
Volume | 132,438 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $7.88 |
52-Week Low | $0.48 | $3.96 |
Typical Hold Time | 16 Days | 18 Days |
Enterprise Value | $3.79M | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Under Armour (UA) trades at $4.70, down 0.42% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company faces significant fundamental challenges with declining revenue ($5.16B in 2025 to $4.9B in 2026) and negative profitability metrics, including a -9.99% net income margin and -29.82% ROE. Recent earnings show volatility with two beats and one miss in the last four quarters, while cash flow remains negative across all categories.
The outlook remains challenging with declining revenue trends and persistent profitability issues offset by relatively low valuation multiples. Investment opportunity exists if management can stabilize sales and improve margins, but risks include continued consumer demand weakness and competitive pressures in the athletic apparel sector. Analyst sentiment is mixed with 41% buy ratings but growing concerns about the company's turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
